RA Capital fund buys 6,387 Hemab Therapeutics shares

Hemab Therapeutics Holdings, Inc. reported an insider open-market purchase by entities managed by RA Capital Management.

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. reported an insider open-market purchase by entities managed by RA Capital Management. An RA Capital-affiliated fund bought 6,387 shares of common stock at a weighted average price of $24.90 per share, with trade prices ranging from $24.70 to $25.00. Following this transaction, the fund indirectly holds 6,372,170 shares of Hemab Therapeutics common stock, while related Nexus funds report indirect holdings of 354,938 and 1,009,052 shares. RA Capital Management, its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.

Insights

Equity ownership analyst

RA Capital-managed funds increased their indirect stake through a modest open-market purchase.

RA Capital-affiliated vehicles acquired 6,387 shares of Hemab Therapeutics common stock at a weighted average of $24.90 per share, with trades executed between $24.70 and $25.00. The transaction is classified as an open-market purchase.

After the trade, one RA Capital fund holds 6,372,170 shares, while related Nexus funds report 354,938 and 1,009,052 shares, all as indirect holdings. RA Capital Management and principals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership beyond their pecuniary interests, indicating the shares are held primarily at the fund level.

Insider Trade Summary

Net Buyer: 6,387 shares

Net Buy 3 txns

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner

Bought 6,387 shs ($159K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	6,387	$24.90	$159K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,736,160 shares (Indirect, See footnotes)

Footnotes (5)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.70 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
3. F3. Held directly by the Fund.
4. F4. Held directly by Nexus Fund II.
5. F5. Held directly by Nexus Fund IV.

Key Figures

Shares purchased: 6,387 shares Weighted average price: $24.90/share Trade price range: $24.70–$25.00/share +3 more

6 metrics

Shares purchased 6,387 shares Open-market purchase of Hemab Therapeutics common stock

Weighted average price $24.90/share Average price for 6,387 purchased shares

Trade price range $24.70–$25.00/share Range of prices for individual purchase trades

Fund holdings after trade 6,372,170 shares Indirect holdings of one RA Capital fund after purchase

Nexus II holdings 354,938 shares Indirect Nexus II Fund position in Hemab Therapeutics

Nexus IV holdings 1,009,052 shares Indirect Nexus IV Fund position in Hemab Therapeutics

Key Terms

weighted average price, open-market purchase, indirect, beneficial ownership, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect financial

"ownership_type": "indirect""

beneficial ownership financial

"disclaim beneficial ownership of any of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of their pecuniary interest therein."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RA Capital report for COAG on this Form 4?

An RA Capital-managed fund reported buying 6,387 shares of Hemab Therapeutics common stock. The purchase was an open-market transaction at a weighted average price of $24.90 per share, with individual trades between $24.70 and $25.00.

At what price did the RA Capital fund buy Hemab Therapeutics (COAG) shares?

The RA Capital-affiliated fund bought COAG shares at a weighted average price of $24.90. Individual trades occurred in a range from $24.70 to $25.00 per share, as disclosed in the Form 4 footnotes.

How many Hemab Therapeutics (COAG) shares does the RA Capital fund hold after this trade?

Following the purchase, the RA Capital Healthcare Fund reports holding 6,372,170 shares of Hemab Therapeutics common stock indirectly. Separate Nexus funds associated with RA Capital report additional indirect holdings of 354,938 and 1,009,052 shares.

Who is listed as the reporting person on the Hemab Therapeutics (COAG) Form 4?

Reporting persons include RA Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus II Fund LP, RA Capital Nexus IV Fund LP, Peter Kolchinsky, and Rajeev Shah, with the entities holding shares indirectly and individuals disclaiming most beneficial ownership.

Do Peter Kolchinsky and Rajeev Shah personally own the COAG shares reported on this Form 4?

The filing states that RA Capital Management, its general partner, the fund, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest, indicating the positions are primarily at the fund level.

What type of transaction code is shown for the COAG insider trade?

The Form 4 lists transaction code "P" for the COAG trade, meaning an open-market or private purchase. Two additional entries are classified as holdings, reflecting indirect positions without new buy or sell activity on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		P		6,387	A	$24.9(1)	6,372,170	I	See footnotes(2)(3)
Common Stock								1,009,052	I	See footnotes(2)(4)
Common Stock								354,938	I	See footnotes(2)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.70 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

3. Held directly by the Fund.

4. Held directly by Nexus Fund II.

5. Held directly by Nexus Fund IV.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	05/14/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P.	05/14/2026
	/s/ Peter Kolchinsky, individually	05/14/2026
	/s/ Rajeev Shah, individually	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)